The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Challenges in managing vulnerable older adults with newly diagnosed metastatic PDAC
Efrat Dotan, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses the unique challenges faced by older adults with pancreatic cancer, a condition often diagnosed at a median age of 70. Dr Dotan highlights that these patients frequently contend with multiple comorbidities, functional impairments, nutritional issues, and cognitive challenges, all of which impact their ability to tolerate and benefit from cancer treatments. Addressing these factors is crucial for optimizing care and improving outcomes for this vulnerable population. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Agenus; Amgen; G1 Therapeutics; Incyte; Olympus; Taiho Pharmaceutical
Research Funding – Dragonfly Therapeutics (Inst); Gilead Sciences (Inst); Ipsen (Inst); Kinnate Biopharma (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lutris (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses – Olympus
